California is currently home to 5605 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Recruiting
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Southern California GI and Liver Centers (SCLC), Coronado, California
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
Recruiting
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Dr. Falk Investigational Site, La Jolla, California
Conditions: Eosinophilic Esophagitis
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruiting
The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to last approximately 3 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: City of Hope National Medical Center, Duarte, California
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Recruiting
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: California Dermatology & Clinical Research Institute, Encinitas, California
Conditions: Psoriasis, Obesity
Wearable Activity Tracking to Curb Hospitalizations
Recruiting
This study is being done to collect patient generated health data to predict the risk of patients needing emergency department visits or hospitalization before, during. and after receiving radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Recruiting
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: City of Hope, Duarte, California
Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
Recruiting
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Neuro-Pain Medical Center, Fresno, California
Conditions: Neuropathic Pain, Distal Sensory Polyneuropathy
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
Recruiting
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/17/2025
Locations: Profound Research, LLC, Carlsbad, California
Conditions: Alzheimer Disease
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Recruiting
The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with PSMA-positive mCRPC who progressed on a prior ARPI treatment with normal renal function or mild renal impairment (eGFR ≥ 60ml/min).
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/17/2025
Locations: Stanford University, Palo Alto, California
Conditions: Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
Recruiting
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Ps0039 50162, Fountain Valley, California
Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Recruiting
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of sacituzumab tirumotecan plus enfortumab vedotin (EV). Part 2 will be based on Part 1 results and will evaluate the efficacy, pharmacokinetics, and safety of sacituzumab tirumotecan plus EV in combination with pembrolizumab in participants with advanced urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of California San Francisco HDFCCC ( Site 4044), San Francisco, California
Conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Recruiting
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/17/2025
Locations: Research Site, Los Angeles, California
Conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR